


Amendment to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended): A compound according to Formula (I) ~~(4)~~ (I):



wherein:

~~X is selected from the group consisting of CH₂, NR₂, O, NR₂CO, CONR₂ and a bond;~~

~~Y represents O, CH₂ or a bond;~~

~~Z represents H or F;~~

X is selected from the group consisting of: (CH₂)_n, NR₂, O, NR₂CO, CONR₂ and a bond;

Y is selected from the group consisting of: O, CH₂ and a covalent bond;

Z is selected from the group consisting of: hydrogen and fluorine;

R is selected from the group consisting of:

C₂₋₆ alkyl optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl; C₂₋₆ alkenyl optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl; C₂₋₆ alkynyl optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl; (CH₂)_n—C₃₋₆ carbocycle optionally substituted by alkoxy, halogen, or C₁₋₃ alkylsulfanyl; and (CH₂)_n—R₃; ~~{where R₃ is phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4 benzodioxane or benzo[1,3]dioxole; R₃ is optionally substituted by one or more Cl, Br, I, C₁₋₃ alkyl optionally substituted by one to three F, or C₁₋₂ alkoxy, optionally substituted by one to three F};~~

R₁ is selected from the group consisting of:

hydrogen, C₁₋₃ substituted alkyl, C₂₋₃ substituted alkenyl, C₂₋₃ substituted alkynyl, (CH₂)_n—C₃₋₆ substituted carbocycle, aryl, heteroaryl, heterocyclic, and aminocarbonyl; provided that X is (CH₂)_n when R₁ represents aminocarbonyl;

~~R₂ represents~~ is selected from the group consisting of:

hydrogen, ~~or~~ and C_{1-3} substituted alkyl $[[,]]$;

R3 is selected from the group consisting of:

phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane and benzo[1,3]dioxole, each of which is optionally substituted by one or more substituents each independently selected from: Cl, Br, I, C_{1-3} alkyl optionally substituted by one to three F, and C_{1-2} alkoxy, optionally substituted by one to three F;


X represents $(CH_2)_n$, NR_2 , O, NR_2CO , $CONR_2$ or a bond;

Y represents O, CH_2 or a covalent bond;

Z represents hydrogen or fluorine; preferably fluoroine; and

n represents an ~~integer~~ integer between 0 and 2; or a pharmaceutically acceptable salt $[[,]]$ or solvate $[[,]]$ or physiologically functional derivative thereof.

2. (Currently amended): A compound ~~as claimed in~~ according to claim 1, ~~or a pharmaceutically acceptable salt or solvate thereof~~, with the following absolute configuration:



~~wherein:~~

~~— X is selected from the group consisting of CH_2 , NR_2 , O, NR_2CO , $CONR_2$ and a bond;~~

~~Y represents O, CH_2 or a bond;~~

~~Z represents H or F $[[,]]$;~~

3. (Currently amended): A compound ~~as claimed in~~ according to claim 1, wherein X $[[=]]$ is CH_2 or a bond; or a pharmaceutically acceptable salt $[[,]]$ or solvate $[[,]]$ or ~~physiologically functional derivative thereof.~~

4. (Currently amended): A compound ~~as claimed in~~ according to claim 1, wherein X $[[=]]$ is NR_2 ; or a pharmaceutically acceptable salt $[[,]]$ or solvate $[[,]]$ or ~~physiologically functional derivative thereof.~~

5. (Currently amended): A compound according to claim 3 selected from the group consisting of:

N-[(R)-2-(5-Benzo[1,3]dioxol-5-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

N-Hydroxy-N-{(R)-2-[5-(7-methoxy-benzofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydroquinolin-6-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydro-quinolin-8-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;

N-Hydroxy-N-{(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-{(R)-2-[5-(2,3-Dichloro-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy formamide;

N-Hydroxy-N-{(R)-2-[5-(4-methoxy-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl} - formamide;

N-((R)-2-{5-[4-(4-Acetyl-piperazin-1-yl)-phenoxy-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-N-hydroxy-formamide;

N-Hydroxy-N-{(R)-2-[5-(1-methyl-1H-pyrrol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-2-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-

formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-
formamide;

N-Hydroxy-N-[(R)-2-[5-(2,6-dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}
formamide;

N-Hydroxy-N-[(R)-2-[5-(1H-indol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;

N-[(R)-2-[(S)-5-(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-N-hydroxy-formamide;

N-[(R)-2-(5-Benzofuran-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy-
formamide;

N-Hydroxy-N-[(R)-2-(5-pyrimidin-2-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-[(R)-2-[5-(2,3-Dihydro-benzo[d]isoxazol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-N-hydroxy-formamide;

N-Hydroxy-N-[(R)-2-(5-phenoxy-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-Hydroxy-N-[(R)-2-[(S)-5-(1,2,3,4-tetrahydro-isoquinolin-3-yl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-formamide;

N-Hydroxy-N-[(R)-2-[5-(4-imidazol-1-yl-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-formamide;

N-Hydroxy-N-[(R)-2-[5-(quinolin-6-yloxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-
formamide;

5-[(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl]-[1,3,4]oxadiazole-2-carboxylic
acid phenylamide;

N-Hydroxy-N-[(R)-2-(5-phenylaminomethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-
formamide;

N-[(R)-2-[5-(2-Chloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-
formamide;

N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclohexyl-propyl]-N-hydroxyformamide.

N-[(R)-2-[5-[2-(1H-Benzoimidazol-2-yl)-ethyl]-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-
formamide;

N-Hydroxy-N-[(R)-2-[5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-
heptyl]-formamide;

N-Hydroxy-N-{(R)-2-[5-(3-methyl-isoxazol-5-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
N-Hydroxy-N-{(R)-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
N-Hydroxy-N-(2-{5-[(4-trifluoromethyl-pyrimidin-2-ylamino)-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;
N-{(R)-2-[5-(1H-Benzimidazol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;
N-Hydroxy-N-[(R)-2-(5-morpholin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-Hydroxy-N-((R)-2-{5-[(3-trifluoromethyl-phenylamino)-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;
N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclopentyl-propyl]-N-hydroxyformamide;
N-Hydroxy-N-[(R)-2-(5-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide; and
N-Hydroxy-N-((R)-2-{5-[2-(1H-indol-3-yl)-ethyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;
and pharmaceutically acceptable salts or solvates thereof.

6. (Currently amended): A compound according to claim 5 selected from the group consisting of:

N-Hydroxy-[(R)-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
N-(5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazol-2-yl)-benzamide;
N-{(R)-2-[5-(Chloro-trifluoromethyl-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide;
N-Hydroxy-N-{(R)-2-[5-(methyl-phenyl-amino)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;
Benzo[1,3]dioxole-5-carboxylic acid (5-{(R)-1-[(formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazol-1,2-yl)-amide;
N-{(R)-2-[5-(3,5-Dichloro-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy formamide;
N-[(S)-2-Fluoro-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy formamide; and
N-{(R)-2-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-formamide; and pharmaceutically acceptable salts or solvates thereof.

7. (Currently amended): A method of treating a bacterial infection by administering to a subject in need of such treatment a compound according to claim 1; or a pharmaceutically acceptable salt or solvate thereof.

8. (New) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.